(4-Methylphenyl)(1-vinyl-1H-benzimidazol-2-yl)methanone | 840503-09-5

• 分子结构分类: 有机化合物 - 有机氧化合物
• 英文名称: (4-Methylphenyl)(1-vinyl-1H-benzimidazol-2-yl)methanone
• 英文别名: (1-ethenylbenzimidazol-2-yl)-(4-methylphenyl)methanone
• CAS: 840503-09-5
• 化学式: C₁₇H₁₄N₂O
• 分子量: 262.311
• InChiKey: SRMLPTZJKCQDDR-UHFFFAOYSA-N

物化性质

• 沸点：
  469.1±38.0 °C(Predicted)
• 密度：
  1.13±0.1 g/cm3(Predicted)

计算性质

• 辛醇/水分配系数(LogP)：
  4.1
• 重原子数：
  20
• 可旋转键数：
  3
• 环数：
  3.0
• sp3杂化的碳原子比例：
  0.06
• 拓扑面积：
  34.9
• 氢给体数：
  0
• 氢受体数：
  2

反应信息

• 作为反应物：
  描述：

  (4-Methylphenyl)(1-vinyl-1H-benzimidazol-2-yl)methanone 在 N-甲基二环己基胺 、 苄基三乙基氯化铵 、 palladium diacetate 、 三氟乙酸 作用下， 以 氯仿 、 N,N-二甲基甲酰胺 为溶剂， 生成 2-methyl-2-[3-[2-[2-(4-methylbenzoyl)benzimidazol-1-yl]ethenyl]phenoxy]propanoic acid
  参考文献：
  名称：

  Synthesis and pharmacological evaluation of novel benzoylazole-based PPAR α/γ activators

  摘要：

  In our search for new PPAR alpha/gamma agonists, we designed and synthesized a series of benzoylazole-based carboxylic acids. Compound 9 showed potent PPAR gamma partial agonistic activity with modest PPAR alpha agonistic activity. The sodium salt of 9 (9Na) demonstrated potent efficacy in lowering both blood glucose and lipids in an animal model without causing significant body weight gain, a well-known side effect associated with PPAR gamma full agonists. (C) 2011 Elsevier Ltd. All rights reserved.

  DOI：

  10.1016/j.bmcl.2011.02.032
• 作为产物：
  描述：

  苯并咪唑 在 caesium carbonate 、 1,8-二氮杂双环[5.4.0]十一碳-7-烯 、 三乙胺 作用下， 以 吡啶 、 二甲基亚砜 、 丙酮 为溶剂， 生成 (4-Methylphenyl)(1-vinyl-1H-benzimidazol-2-yl)methanone
  参考文献：
  名称：

  Synthesis and pharmacological evaluation of novel benzoylazole-based PPAR α/γ activators

  摘要：

  In our search for new PPAR alpha/gamma agonists, we designed and synthesized a series of benzoylazole-based carboxylic acids. Compound 9 showed potent PPAR gamma partial agonistic activity with modest PPAR alpha agonistic activity. The sodium salt of 9 (9Na) demonstrated potent efficacy in lowering both blood glucose and lipids in an animal model without causing significant body weight gain, a well-known side effect associated with PPAR gamma full agonists. (C) 2011 Elsevier Ltd. All rights reserved.

  DOI：

  10.1016/j.bmcl.2011.02.032

文献信息

• Novel heteroaryl derivative
  申请人：Watanabe Ken-ichi

  公开号：US20060194857A1

  公开（公告）日：2006-08-31

  A heteroaryl derivative of the formula (1): (wherein Ring Z is an optionally substituted heteroaryl, R 1 is a carboxyl group or an alkoxycarbonyl group, etc., W 1 and W 2 are an optionally substituted lower alkylene, Ar 1 is an optionally substituted arylene or an optionally substituted heteroarylene, W 3 is a single bond, a lower alkylene, a lower alkenylene, etc., W 4 is a single bond, —NR 10 —, etc., Ar 2 is an optionally substituted aryl or an optionally substituted heteroaryl), or a prodrug thereof, or a pharmaceutically acceptable salt thereof.

  式（1）中，环Z是一种可选的取代杂环基，R1是羧基或烷氧羰基基团等，W1和W2是可选的取代的低碳基链，Ar1是可选的取代芳基或可选的取代杂芳基，W3是单键，低碳基链，低烯基链等，W4是单键，—NR10—等，Ar2是可选的取代芳基或可选的取代杂芳基的杂环基，或其前体药物，或其药物可接受的盐。
• Heteroaryl derivative
  申请人：Dainippon Sumitomo Pharma Co. ,Ltd.

  公开号：US07425642B2

  公开（公告）日：2008-09-16

  A heteroaryl derivative of the formula (1): (wherein Ring Z is an optionally substituted heteroaryl, R1 is a carboxyl group or an alkoxycarbonyl group, etc., W1 and W2 are an optionally substituted lower alkylene, Ar1 is an optionally substituted arylene or an optionally substituted heteroarylene, W3 is a single bond, a lower alkylene, a lower alkenylene, etc., W4 is a single bond, —NR10—, etc., Ar2 is an optionally substituted aryl or an optionally substituted heteroaryl), or a prodrug thereof, or a pharmaceutically acceptable salt thereof.

  式（1）的杂环取代物：（其中环Z是可选取代的杂环基，R1是羧基或烷氧羰基等，W1和W2是可选取代的较低烷基，Ar1是可选取代的芳基或可选取代的杂芳基，W3是单键，较低烷基，较低烯基等，W4是单键，—NR10—等，Ar2是可选取代的芳基或可选取代的杂芳基），或其前药，或其药学上可接受的盐。
• NOVEL HETEROARYL DERIVATIVE
  申请人：Dainippon Sumitomo Pharma Co., Ltd.

  公开号：EP1647546B1

  公开（公告）日：2012-05-02
• US7425642B2
  申请人：——

  公开号：US7425642B2

  公开（公告）日：2008-09-16